TD Cowen on Soleno Therapeutics Inc. (SLNO): 'Patient Death Not Treatment Related; Vykat XR Safety Continues To Be Consistent'
Tweet Send to a Friend
TD Cowen analyst Tyler Van Buren reiterated a Buy rating and $120.00 price target on Soleno Therapeutics Inc. (NASDAQ: SLNO).The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
